Although ezogabine has also shown some benefits in seizure control in several KCNQ2 encephalopathy infants, including an individual heterozygous for A337T (Weckhuysen et al., 2013; Millichap et al., 2016), side effects have limited its use. Here, KCNQ2 is linked to Encephalopathy.